KRYS
Krystal Biotech, Inc.
Stock
$322.28−3.03 (−0.93%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $440M | $389M | $291M | $51M | $0 | $0 |
| R&D | $59M | $58M | $54M | $46M | $42M | $28M |
| SG&A | $160M | $147M | $114M | $98M | $78M | — |
| Operating income | $198M | $161M | $66M | −$110M | −$145M | −$68M |
| Non-operating income | $29M | $28M | $30M | $123M | $5.2M | −$1.3M |
| Pretax income | $227M | $189M | $95M | $13M | −$140M | −$70M |
| Taxes | −$15M | −$15M | $6.2M | $2.0M | $0 | $0 |
| Net income | $241M | $205M | $89M | $11M | −$140M | −$70M |
| Diluted EPS | $7.97 | $6.84 | $3.00 | $0.39 | −$5.49 | −$3.13 |
| Diluted shares | — | 30.0M | 29.7M | 27.8M | 25.5M | 22.2M |
| Revenue growth | — | +33.9% | +473.0% | — | — | — |
| Operating margin | 44.9% | 41.5% | 22.6% | −216.2% | — | — |
| Net margin | 54.8% | 52.6% | 30.7% | 21.6% | — | — |